{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:05:22Z","timestamp":1789236322113,"version":"build-2803163510"},"reference-count":48,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common, often debilitating side effect of several chemotherapeutic agents, particularly taxanes and platinum compounds. Current management strategies remain limited, with few agents demonstrating consistent efficacy. Our aim was to evaluate the efficacy and safety of a novel topical cream containing 1% amitriptyline and 0.5% ketamine in alleviating CIPN symptoms in oncology patients. Methods: A prospective observational study was conducted at Barzilai Medical Center following the approval of the local ethics committee. Thirty-seven patients (30 females, 7 males; age 40\u201375) with CIPN following taxane or platinum-based chemotherapy were treated with a topical cream applied three times daily for 28 weeks. Pain intensity was assessed using the Visual Analog Scale (VAS). Inclusion and exclusion criteria were strictly applied to ensure a homogenous cohort. Results: Initial mean VAS was 7 (range 6\u201310), which decreased to a final mean VAS of 3 (range 1\u20137). Two patients withdrew from the study, and 27 out of 35 evaluable patients (77.14%) reported significant symptoms relief. A statistically significant reduction in pain scores (p = 0.00005) was seen in our study. Only mild, transient erythema was reported as a side effect. Conclusions: This is the first clinical evaluation of a topical combination with new concentrations of amitriptyline and ketamine for CIPN. The results suggest this formulation offers a safe and effective option for symptomatic relief. Larger randomized controlled trials and exploration of transdermal delivery systems are warranted to validate these findings and optimize treatment outcomes.<\/jats:p>","DOI":"10.3390\/cancers17203321","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T07:17:52Z","timestamp":1760512672000},"page":"3321","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Management of Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Oncologic Patients\u2014A New Promise? Preliminary Results"],"prefix":"10.3390","volume":"17","author":[{"given":"Ron","family":"Batash","sequence":"first","affiliation":[{"name":"Orthopedic Oncology Unit, Tel Aviv University, Wolfson, Holon 5822012, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Asna","sequence":"additional","affiliation":[{"name":"Oncology Department, The Hebrew University of Jerusalem, Sharei Zedek, Jerusalem 9103102, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara HaJ","family":"Ali","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Ben Gurion University, Beer Sheva 8499000, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Charkovsky","sequence":"additional","affiliation":[{"name":"Oncology Department, Barzilai Medical Center, Ashkelon 7830604, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2275-6805","authenticated-orcid":false,"given":"Murad","family":"Asali","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Ben Gurion University, Beer Sheva 8499000, Israel"},{"name":"Oncology Department, Barzilai Medical Center, Ashkelon 7830604, Israel"},{"name":"Urology Department, Barzilai Medical Center, Ben Gurion University, Ashkelon 7830604, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Pelles","sequence":"additional","affiliation":[{"name":"Oncology Department, Barzilai Medical Center, Ashkelon 7830604, Israel"},{"name":"Oncology Department, Tel Aviv University, Suarski Medical Center, Tel Aviv 6423906, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Schaffer","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Ben Gurion University, Beer Sheva 8499000, Israel"},{"name":"Oncology Department, Barzilai Medical Center, Ashkelon 7830604, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"ref_1","first-page":"489","article-title":"Peripheral Neuropathies Especially in Cancer Patients: Focus on Chemotherapy-induced Peripheral Neuropathies and Post-Herpetic Neuralgia","volume":"8","author":"Kanbayashi","year":"2015","journal-title":"Int. J. Cancer Res. Prev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.12688\/f1000research.8053.1","article-title":"Chemotherapy-induced peripheral neuropathy: An update on the current understanding","volume":"5","author":"Addington","year":"2016","journal-title":"F1000Res"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"iv45","DOI":"10.1093\/neuonc\/nos203","article-title":"Peripheral neuropathies from chemotherapeutics and targeted agents: Diagnosis, treatment, and prevention","volume":"14","author":"Grisold","year":"2012","journal-title":"Neuro-oncology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.2174\/0929867326666190107163756","article-title":"Management of Peripheral Neuropathy Induced by Chemotherapy","volume":"26","author":"Fradkin","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: A Major Update to the DrugBank Database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Kerckhove, N., Collin, A., Cond\u00e9, S., Chaleteix, C., Pezet, D., and Balayssac, D. (2017). Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00086"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ctrv.2011.07.003","article-title":"A role for maintenance therapy in managing sarcoma","volume":"38","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/1758834017712963","article-title":"Treatment of advanced, metastatic soft tissue sarcoma: Latest evidence and clinical considerations","volume":"9","author":"In","year":"2017","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/mpo.1210","article-title":"Painful peripheral neuropathy after treatment with high-dose ifosfamide","volume":"37","author":"Frisk","year":"2001","journal-title":"Med. Pediatr. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/13577149878055","article-title":"Long-Term Neurotoxicity of Chemotherapy in Adolescents and Young Adults Treated for Bone and Soft Tissue Sarcomas","volume":"2","author":"Earl","year":"1998","journal-title":"Sarcoma"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.12688\/f1000research.21625.1","article-title":"Recent advances in understanding chemotherapy-induced peripheral neuropathy","volume":"9","year":"2020","journal-title":"F1000Res"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/j.pain.0000000000001540","article-title":"Chemotherapy-induced peripheral neuropathy: Where are we now?","volume":"160","author":"Colvin","year":"2019","journal-title":"Pain"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1089\/jpm.2021.0512","article-title":"Pharmacological and Nonpharmacological Management of Chemotherapy-Induced Peripheral Neuropathy: A Scoping Review of Randomized Controlled Trials","volume":"25","author":"Jones","year":"2022","journal-title":"J. Palliat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"102124","DOI":"10.1016\/j.ejon.2022.102124","article-title":"Evaluating the safety, feasibility, and efficacy of non-invasive neuromodulation techniques in chemotherapy-induced peripheral neuropathy: A systematic review","volume":"58","author":"Wang","year":"2022","journal-title":"Eur. J. Oncol. Nurs."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1011-1344(99)00155-4","article-title":"Effects of 780 nm diode laser irradiation on blood microcirculation: Preliminary findings on time-dependent T1-weighted contrast-enhanced magnetic resonance imaging (MRI)","volume":"54","author":"Schaffer","year":"2000","journal-title":"J. Photochem. Photobiol. B Biol."},{"key":"ref_17","first-page":"52","article-title":"Evaluating laser photobiomodulation for chemotherapy-induced peripheral neuropathy: A randomised phase II trial","volume":"31","author":"Teng","year":"2022","journal-title":"Support. Care Cancer"},{"key":"ref_18","first-page":"355","article-title":"Influence of photobiomodulation on sensory symptoms, balance, and gait speed in chemotherapy-induced peripheral neuropathy","volume":"33","author":"Santamarina","year":"2025","journal-title":"Support. Care Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ygyno.2016.11.013","article-title":"The effect of photobiomodulation on chemotherapy-induced peripheral neuropathy: A randomized, sham-controlled clinical trial","volume":"144","author":"Argenta","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_20","first-page":"5509","article-title":"The use of photobiomodulation therapy for the prevention of chemotherapy-induced peripheral neuropathy: A randomized, placebo-controlled pilot trial (NEUROLASER trial)","volume":"30","author":"Joy","year":"2022","journal-title":"Support. Care Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1053\/j.seminoncol.2021.09.004","article-title":"Chemotherapy-induced peripheral neuropathy and rehabilitation: A review","volume":"48","author":"Zhang","year":"2021","journal-title":"Semin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Li, Y., Lustberg, M.B., and Hu, S. (2021). Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy. Cancers, 13.","DOI":"10.3390\/cancers13040766"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Crichton, M., Yates, P.M., Agbejule, O.A., Spooner, A., Chan, R.J., and Hart, N.H. (2022). Non-Pharmacological Self-Management Strategies for Chemotherapy-Induced Peripheral Neuropathy in People with Advanced Cancer: A Systematic Review and Meta-Analysis. Nutrients, 14.","DOI":"10.3390\/nu14122403"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/jamainternmed.2024.2354","article-title":"Preventive Effect of Neuromuscular Training on Chemotherapy-Induced Neuropathy: A Randomized Clinical Trial","volume":"184","author":"Streckmann","year":"2024","journal-title":"JAMA Intern. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Chen, X., Gan, Y., Au, N.P.B., and Ma, C.H.E. (2024). Current understanding of the molecular mechanisms of chemotherapy-induced peripheral neuropathy. Front. Mol. Neurosci., 17.","DOI":"10.3389\/fnmol.2024.1345811"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.neulet.2014.10.014","article-title":"Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms?","volume":"596","author":"Carozzi","year":"2015","journal-title":"Neurosci. Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/jnnp-2021-328323","article-title":"Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: Clinical and experimental evidence","volume":"94","author":"Park","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ollodart, J., Steele, L.R., Romero-Sandoval, E.A., Strowd, R.E., and Shiozawa, Y. (2024). Contributions of neuroimmune interactions to chemotherapy-induced peripheral neuropathy development and its prevention\/therapy. Biochem. Pharmacol., 222.","DOI":"10.1016\/j.bcp.2024.116070"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Zaj\u0105czkowska, R., Kocot-K\u0119pska, M., Leppert, W., Wrzosek, A., Mika, J., and Wordliczek, J. (2019). Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061451"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Pozzi, E., Terribile, G., Cherchi, L., Di Girolamo, S., Sancini, G., and Alberti, P. (2024). Ion Channel and Transporter Involvement in Chemotherapy-Induced Peripheral Neurotoxicity. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25126552"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Brandolini, L., D\u2019Angelo, M., Antonosante, A., Cimini, A., and Allegretti, M. (2019). Chemokine Signaling in Chemotherapy-Induced Neuropathic Pain. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20122904"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/j.pain.0000000000001922","article-title":"Diabetic neuropathy and neuropathic pain: A (con)fusion of pathogenic mechanisms?","volume":"161","author":"Calcutt","year":"2020","journal-title":"Pain"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Galiero, R., Caturano, A., Vetrano, E., Beccia, D., Brin, C., Alfano, M., Di Salvo, J., Epifani, R., Piacevole, A., and Tagliaferri, G. (2023). Peripheral Neuropathy in Diabetes Mellitus: Pathogenetic Mechanisms and Diagnostic Options. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043554"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Mizukami, H., and Osonoi, S. (2020). Pathogenesis and Molecular Treatment Strategies of Diabetic Neuropathy Collateral Glucose-Utilizing Pathways in Diabetic Polyneuropathy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010094"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Shastri, A., Al Aiyan, A., Kishore, U., and Farrugia, M.E. (2023). Immune-Mediated Neuropathies: Pathophysiology and Management. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087288"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e209725","DOI":"10.1212\/WNL.0000000000209725","article-title":"Antibodies in Autoimmune Neuropathies: What to Test, How to Test, Why to Test","volume":"103","author":"Querol","year":"2024","journal-title":"Neurology"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Guo, Z. (2023). Ganglioside GM1 and the Central Nervous System. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119558"},{"key":"ref_39","first-page":"833","article-title":"A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA","volume":"19","author":"Barton","year":"2010","journal-title":"Support. Care Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Mattar, M., Umutoni, F., Hassan, M.A., Wamburu, M.W., Turner, R., Patton, J.S., Chen, X., and Lei, W. (2024). Chemotherapy-Induced Peripheral Neuropathy: A Recent Update on Pathophysiology and Treatment. Life, 14.","DOI":"10.3390\/life14080991"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1111\/bph.13887","article-title":"Single and combined effects of \u0394(9)-tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain","volume":"174","author":"King","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1124\/jpet.124.002165","article-title":"Chronic Administration of Cannabinoid Agonists ACEA, AM1241, and CP55,940 Induce Sex-Specific Differences in Tolerance and Sex Hormone Changes in a Chemotherapy-Induced Peripheral Neuropathy","volume":"391","author":"Barnes","year":"2024","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"15347354211061739","DOI":"10.1177\/15347354211061739","article-title":"Topical Cannabinoids for Treating Chemotherapy-Induced Neuropathy: A Case Series","volume":"20","author":"McAllister","year":"2021","journal-title":"Integr. Cancer Ther."},{"key":"ref_44","first-page":"40","article-title":"Adverse events associated with the use of cannabis-based products in people living with cancer: A systematic scoping review","volume":"33","author":"Cheah","year":"2024","journal-title":"Support. Care Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Clavo, B., Rodr\u00edguez-Abreu, D., Galv\u00e1n, S., Federico, M., Mart\u00ednez-S\u00e1nchez, G., Ramallo-Fari\u00f1a, Y., Antonelli, C., Ben\u00edtez, G., Rey-Baltar, D., and Jorge, I.J. (2022). Long-term improvement by ozone treatment in chronic pain secondary to chemotherapy-induced peripheral neuropathy: A preliminary report. Front. Physiol., 13.","DOI":"10.3389\/fphys.2022.935269"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"15347354241307038","DOI":"10.1177\/15347354241307038","article-title":"Long-Term Effects of Ozone Treatment in Patients with Persistent Numbness and Tingling Secondary to Chemotherapy-Induced Peripheral Neuropathy. A Retrospective Study","volume":"24","author":"Clavo","year":"2025","journal-title":"Integr. Cancer Ther."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Desforges, A.D., Hebert, C.M., Spence, A.L., Reid, B., Dhaibar, H.A., Cruz-Topete, D., Cornett, E.M., Kaye, A.D., Urits, I., and Viswanath, O. (2022). Treatment and diagnosis of chemotherapy-induced peripheral neuropathy: An update. Biomed. Pharmacother., 147.","DOI":"10.1016\/j.biopha.2022.112671"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"12010","DOI":"10.1200\/JCO.2025.43.16_suppl.12010","article-title":"Alliance A221805: Duloxetine to prevent oxaliplatin-induced chemotherapy-induced peripheral neuropathy (CIPN)\u2014A randomized, double-blind, placebo-controlled phase II study","volume":"43","author":"Smith","year":"2025","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/20\/3321\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T07:40:47Z","timestamp":1760514047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/20\/3321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":48,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["cancers17203321"],"URL":"https:\/\/doi.org\/10.3390\/cancers17203321","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]}}}